Welcome back to the Psychedelic Invest week in review. Here are the stories that moved the psychedelic sector during the week of November 24–30, 2025 — from clinical readouts to regulatory shifts and the capital flowing through the space.
Optimi Health Corp. (OPTH): Optimi Health selected to supply MDMA for MAPS Israel's 168-patient PTSD trial
Optimi Health said it will supply GMP 40 mg and 60 mg MDMA capsules for MAPS Israel's 'Healing October 7th' clinical program, an open-label, multicenter PTSD study approved by the Israeli Ministry of Health. The 168-participant trial, sponsored by Sheba Medical Center, compares individual versus group MDMA-assisted therapy, and Optimi confirmed it had already completed its first export shipment to Israel — extending its international commercial supply footprint beyond Australia.
Source: biospace.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.